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Abstract
The identification of drug resistance pathways and approaches to target these 
pathways remains a significant and important challenge in cancer biology. Here, 
we address this challenge in the context of ongoing efforts to advance phosphati-
dylinositol 3-kinase (PI3K) inhibitors for the treatment of PI3K-aberrant cancers. 
While PI3K inhibitors have had tremendous success in some diseases, such as breast 
cancer, early clinical trials in other malignancies, such as head and neck squamous 
cell carcinoma (HNSCC), have not had the same level of success. Since HNSCC and 
other cancers display relatively high PI3K pathway alteration rates (>45%), these 
underwhelming results suggest that additional or unexpected factors may contrib-
ute to the lower response rates. Here, we highlight some of the emerging functional 
genomic and sequencing approaches being used to identify predictive biomarkers 
of PI3K inhibitor response using both cancer cell lines and clinical trial specimens. 
Importantly, these approaches have uncovered both innate genetic and adaptive 
mechanisms driving PI3K inhibitor resistance. In this chapter, we describe recent 
technological advances that have revolutionized our understanding of PI3K inhibitor 
resistance pathways in HNSCC and highlight how these and other approaches lay the 
groundwork to make significant strides in our understanding of molecular pharma-
cology in the cancer field.
Keywords: PI3K, targeted therapy, drug combination, drug screening, drug 
resistance
1. Introduction
Head and neck squamous cell carcinomas (HNSCCs) are malignant neoplasms 
that can occur in regions including the oral cavity, oropharynx, and larynx. HNSCC 
is the sixth most common cancer, by incidence, worldwide and constitutes approxi-
mately 4% of all cancers globally [1–3]. Tobacco use, alcohol consumption, and/or 
infection with oncogenic high-risk types of HPV, primarily HPV16, are regarded as 
the major risk factors for HNSCC [4]. Although traditional treatments for HNSCC 
include surgery, radiotherapy, and cytotoxic chemotherapy [1], these approaches 
have only modestly reduced the mortality of HNSCC. In fact, only 40–50% of 
patients with HNSCC survive for 5 years following diagnosis [5].
Molecular Pharmacology
2
2. The phosphatidylinositol 3-kinase (PI3K) pathway in HNSCC
HNSCC sequencing studies have identified highly prevalent PI3K pathway 
alterations that activate PI3K signaling. Following activation by receptor tyrosine 
kinases (RTKs) and/or G-protein coupled receptors (GPCRs), PI3K phosphorylates 
phosphatidylinositol (4,5)-bisphosphate (PIP2) into an essential second messen-
ger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [6]. PIP3 then recruits and 
activates proteins like PDK1 and AKT to mediate PI3K’s pro-survival functions 
(Figure 1A). As a tumor suppressor, PTEN dephosphorylates PIP3 into PIP2 to 
prevent downstream signal propagation; the deregulation of PTEN is also related to 
multiple cancers including HNSCC [7].
There are three classes of PI3K (Class I, Class II, and Class III), and Class I 
PI3K is further divided into Class IA and Class IB [8]. Among the Class IA PI3Ks is 
p110alpha encoded by the gene PIK3CA, which represents the catalytic subunit and 
alpha isoform of PI3K. Importantly, PIK3CA is the most frequently altered gene in 
the PI3K pathway across all tumors and in HNSCC [9–11]. Alterations of other Class 
I PI3Ks isoforms, like p110β, and of some regulatory isoforms have been detected 
in various cancers, albeit with a relatively low frequency [12] (Figure 2). Although 
studies have also examined Class II and Class III PI3Ks, more research is needed to 
understand their role in human disease [16].
Functionally, the PI3K signaling pathway has a wide range of intracellular effects, 
including participation in cell cycle, survival, metabolism, motility, and genomic 
instability [17]. Mutations or other genetic aberrations can lead to hyperactivation 
of PI3K signaling, and in turn increase cell growth and viability. Angiogenesis and 
inflammatory cell recruitment, which are thought to be cancer-promoting, may also 
drive tumor progression and are common in advanced-stage tumors [9, 18].
Figure 1. 
Rationale for PI3K inhibitor combination therapy. (A) The PI3K signaling pathway has diverse cellular 
functions. (B) Alterations in PI3K pathway genes may lead to increased signaling. (C) Resistance to PI3K 
inhibitor monotherapy prevents cell death. (D) Co-targeting PI3K and resistance mechanisms leads to cell 
death.
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The first manuscript detailing PIK3CA mutations in HNSCC was published 
in 2006; this study described “hotspot,” activating mutations (E542K, E545K, 
and H1047R) among other PIK3CA alterations that are less frequent and have 
not been as well characterized [19]. Since then, evidence has continued to sup-
port the significant role of PI3K signaling in HNSCC. The Cancer Genome Atlas 
(TCGA) dataset, one of the largest HNSCC sequencing studies performed to date, 
shows that the PI3K signaling pathway is the most frequently mutated oncogenic 
and targetable signaling pathway in this cancer type [13, 15, 20]. Additionally, 
Chung and co-authors independently found that almost 32% of HNSCC patients 
have PIK3CA mutation or copy number alteration after analyzing 252 HNSCC 
patient samples. This study also indicated that 11% of HPV-positive and 5% of 
HPV-negative HNSCC patients have loss-of-function mutations or copy number 
alterations in PTEN, the gene responsible for restraining PI3K pathway activation 
(Figure 1B) [21].
The frequency of PI3K pathway alteration suggests that inhibitors targeting this 
pathway may be of clinical use, and several teams have advanced PI3K inhibitors to 
test their effectiveness for HNSCC treatment. Early clinical trials demonstrated that 
PI3K inhibitors were safe for use in patients with solid tumors [22, 23], and studies 
evaluated the potential benefits of using pan-PI3K-targeting agents in recurrent and 
metastatic HNSCC specifically. However, PI3K inhibitors have more recently shown 
limitations in efficacy as well as safety (Figure 1C). Jimeno et al. reported in 2015 
that pan-PI3K inhibitor PX-866 did not improve outcomes when added to cytotoxic 
chemotherapy (docetaxel) in unselected recurrent or metastatic (R/M) HNSCC 
patients [24]. Later, Soulieres and colleagues achieved improvements in overall and 
progression-free survival when administering another pan-PI3K inhibitor, BKM120, 
with cytotoxic agent paclitaxel (as compared to paclitaxel alone); this study, the 
BERIL-1 trial, is discussed further below [25]. Unfortunately, BKM120 has not been 
evaluated further due to undesired side effects. Current trials are evaluating the 
clinical effects of other PI3K-targeting drugs (NCT03740100), including those with 
isoform selectivity (NCT02145312, NCT02822482), in HNSCC patients.
The lack of patient selection is one potential contributor to the underwhelming 
efficacy of PI3K inhibitor treatment in HNSCCs to date. Although the majority of 
TCGA HNSCC patients display aberration in one or more PI3K pathway genes [14], 
Figure 2. 
PI3K pathway gene alteration rates in HNSCC tumors from the cancer genome atlas (TCGA). Amplifications, 
deletions, mutations and/or multiple alterations (e.g., amplification and mutation) are shown as indicated  
[13–15].
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the status of any single gene or any group of genes has not been validated as a criti-
cal biomarker of response to PI3K inhibition. This is in contrast to recent data for 
hormone receptor-positive breast cancer, where PI3K inhibitor alpelisib is used in 
combination with fulvestrant to prolong survival for patients with PIK3CA mutant 
tumors [26]. While precision medicine trials across a variety of cancer types have 
also shown a trend supporting PIK3CA alterations as a marker for response to PI3K 
inhibitors [27], PIK3CA mutation has not yet been associated with sensitivity to PI3K 
inhibition in HNSCC trials [24, 28]. Studies evaluating the role of PIK3CA mutations 
in response to PI3K inhibition in HNSCC often do not reach statistical significance or 
have a very limited number of patients enrolling. For example, Janku et al. conducted 
an analysis of responses to PI3K/AKT/mTOR inhibitors in tumors with H1047R 
PIK3CA mutations including four HNSCC patients; after inhibitor treatment, two 
of these patients experienced progressive disease, one had little change in tumor 
burden, and another had an incomplete response to therapy [29]. It is possible that 
the difference in outcomes between tumors with and without PIK3CA mutations has 
not been noted due to an insufficient number of PIK3CA mutant tumors in any single 
clinical trial. Ongoing studies of PI3K inhibitor copanlisib in HNSCC patients with 
PIK3CA mutation or amplification or PTEN loss will better elucidate any potential 
differences in response attributable to PI3K activation (NCT02822482). It is also 
feasible that other features predict responses to PI3K inhibitor. In the recent BERIL-1 
study, which compared outcomes in R/M HNSCC patients (n = 79 per group) treated 
with paclitaxel with or without pan-PI3K inhibitor BKM120, follow-up analysis 
revealed that TP53 alteration, low tumor mutation burden, HPV negativity, and high 
infiltration of tumor infiltrating lymphocytes (TILs) or CD8+ T-cells was associ-
ated with improved response to BKM120. Recent preclinical work has proposed that 
loss-of-function mutations in NOTCH1 may predict response to PI3K inhibition [30]. 
Together these data suggest that a more nuanced understanding of tissue type-
specific factors and PI3K inhibitor response mechanisms may be required to develop 
clinically effective companion diagnostics for this class of inhibitors in HNSCC.
Our recent report indicates that responses to PI3K inhibition, either as mono-
therapy or in combination with other targeted inhibitors, are complex and cannot 
be predicted solely based on genetic mutation, copy number alteration, or RNA 
expression of a single gene (submitted). In this study, a diverse set of HNSCC cell 
lines were treated with PI3K inhibitors of varying isoform selectivity as mono-
therapies. Alpha isoform-targeting agents were clearly more effective than other 
PI3K inhibitors, but the sensitivity profiles for any individual pan- or alpha-isoform 
PI3K inhibitor were more difficult to stratify. This was increasingly true when PI3K 
inhibitors were used in drug combinations: PIK3CA mutation, copy number, RNA 
expression, and HPV status did not prove to be meaningful biomarkers for either 
PI3K and epidermal growth factor receptor (EGFR) inhibitor dual-therapies [31] 
or for other synergistic drug pairs. In the case of PI3Kalpha inhibitor HS-173 and 
FAK inhibitor TAE226, greater synergy was observed in PIK3CA mutant cell lines as 
compared to PIK3CA wildtype cell lines in initial validation experiments. However, 
when this association was tested more rigorously with other PI3K and FAK inhibi-
tors, dual-therapy was beneficial also in many PIK3CA wildtype models; this could 
be due to differences in selectivity or mechanism of action for individual small 
molecule drugs [32]. Thus, PI3K pathway activation, measured at the DNA level 
via mutation or copy number status or at the protein level via relative downstream 
phosphorylation, appears to be an insufficient biomarker for sensitivity in HNSCC 
cell lines; other cellular features, including additional alteration in PI3K pathway 
members (such as downstream mutations in AKT1) or activation of receptor 
tyrosine kinases (perhaps via upstream overexpression of EGFR), may contribute to 
signaling through the PI3K pathway and thereby affect inhibitor responses. Indeed, 
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multifaceted analyses, such as those considering gene sets rather than individual 
genetic changes, may be needed to predict sensitivity. For example, responses to 
EGFR or FAK inhibitor may be better stratified using gene sets incorporating acti-
vation of PI3K, mTOR, or other related signaling nodes instead of PIK3CA muta-
tion status alone. Alternatively, an additional pathway that is changed as a result of 
PI3K activation (e.g., epithelial to mesenchymal transition, cell cycle, or apoptosis) 
may be even more effective in predicting response.
More broadly, activation or blockade of PI3K signaling may impact response 
to other forms of cancer treatment. Clinical trial data have not demonstrated that 
mutation, amplification, or loss of PI3K pathway genes is linked to sensitivity or 
resistance to PI3K inhibitors.  However, recent trials for EGFR-targeting agents have 
noted poorer outcomes following EGFR inhibition in patients with PI3K activation. 
In the phase III E2303 trial, which compared cisplatin with or without cetuximab in 
without cetuximab in R/M HNSCC patients [33], PIK3CA mutation or PTEN loss was 
associated with poor response to EGFR-targeting therapy [34]. This finding was also 
noted in the LUX-H&N1 trial, which compared second-line treatments with afatinib 
and methotrexate in R/M HNSCCs [35]; here, tumors lacking PTEN received inferior 
benefit from afatinib as compared to those with high levels of PTEN [36]. Preclinical 
studies have also noted that PI3K activation or PTEN loss may serve as a biomarker 
for resistance to cetuximab [37, 38] and that PIK3CA mutant HNSCC models may be 
more resistant to cyclin-dependent kinase (CDK) inhibitor palbociclib [39]. Further 
studies are warranted to validate these results in larger, prospective trials.
3.  Combination drug strategies may overcome compensatory PI3K 
inhibitor resistance
3.1 Epidermal growth factor receptor (EGFR)
One of the most widely studied mechanisms of resistance to PI3K inhibition is 
signaling through members of the ERBB family, primarily EGFR, and the down-
stream Ras-MEK-ERK effector pathway. The human ERBB gene family encodes four 
members of the ERBB family of receptors including EGFR/ERBB1/HER1, NEU/
ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4. As a transmembrane receptor, 
EGFR can be activated by ligands including epidermal growth factor (EGF). EGFR 
signaling subsequently activates downstream pathways, including RAS-RAF-MEK-
ERK. MAPK and PI3K-AKT-mTOR signaling pathways, to promote cell proliferation 
and inhibit apoptosis in many head and neck models [40, 41]. EGFR overexpression 
has been reported in the vast majority of HNSCCs [42]. Further genetic dysregula-
tions of EGFR signaling caused by EGFR gene mutation (although rare in head and 
neck cancer) and EGFR gene copy number amplification (approximately 10% of 
cases) also contribute to activated EGFR signaling [41, 43].
Activation of EGFR signaling as a mechanism of PI3K inhibitor resistance 
has been extensively characterized using a wide variety of cell lines (displaying a 
diverse array of genetic alterations) and a large set of ERBB family-targeting drugs 
[1, 31, 44–47]. Early work focused on PIK3CA-amplified HNSCCs demonstrated 
that two-thirds (67%) of cell lines with additional copies of wildtype PIK3CA 
maintained RAS-RAF-MEK-ERK MAPK pathway activity following PI3K inhibitor 
treatment and that two of these models were also sensitive to dual inhibition of 
PI3K and EGFR or MEK [1]. A more recent publication extended this observation 
to a larger panel of ERBB inhibitors and cell lines, including several with PIK3CA 
mutations [31]. Overall, findings from the latter study mirrored those of previous 
publications showing that dual-therapy with PI3K and EGFR inhibitors was often 
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more effective than either monotherapy [44–47], but also extended this observation 
to consider individual classes of ERBB-targeting agents that might result in height-
ened responses when used as part of combination treatments. Results in HNSCC 
cell lines showed that irreversible inhibitors of EGFR were more effective in com-
bination with PI3K inhibitors than reversible ERBB-targeting agents. As previous 
work had primarily considered dual-therapies that included either reversible EGFR 
inhibitors or EGFR-targeting antibodies such as cetuximab, this work was the first 
direct comparison of PI3K inhibitors in combination with distinct pharmacologies 
against EGFR.
Beyond direct inhibition of the receptor tyrosine kinases PI3K and EGFR them-
selves, previous work has also examined drug combinations targeting PI3K and 
EGFR via inhibition of downstream effectors including mTOR and MEK, respec-
tively. Several papers have described synergy with mTOR inhibitors and EGFR 
agents [48–50]. In one of these studies, Jimeno et al. used H1047R PIK3CA mutant 
Detroit 562 cells in a xenograft model and noted improved response to mTOR 
inhibitor temsirolimus and erlotinib. This response co-occurred with changes in 
MAPK and p70 S6 kinase phosphorylation (downstream of EGFR and mTOR, 
respectively) and in Ki67, effects that were not evidenced in less responsive xeno-
graft models or after single-agent treatment. Other work with Detroit 562 in vitro 
showed minimal responses to PI3K inhibitor HS-173 and reversible EGFR inhibi-
tors, including erlotinib, that could be enhanced to synergistic levels with multiple 
irreversible EGFR inhibitors [31]. The combination of erlotinib with mTOR inhibi-
tors (temsirolimus or otherwise) has not been reported in this model. Nevertheless, 
since additional data show that ineffective reversible EGFR inhibitor combinations 
block MAPK phosphorylation [31] (p70 S6 kinase phosphorylation was not tested), 
it is possible that one or more additional effectors, perhaps further downstream of 
MAPK/p70 S6 kinase or as part of a second escape pathway, may be responsible for 
synergistic effects. Alternatively, in vitro and in vivo responses to mTOR and EGFR 
agents in Detroit 562 and potentially other HNSCCs could be dependent on distinct 
mechanisms. PI3K and irreversible EGFR inhibitor combinations have not yet been 
tested in xenografts, but these experiments would enhance our understanding of 
the potential for such dual-therapies to translate clinically.
In light of the synergy observed following treatment with agents targeting the 
PI3K and EGFR pathways in preclinical models, phase I and II trials have been per-
formed to examine these dual-therapies in HNSCC patients. Of these trials, three 
have been completed, all in patients receiving second-line treatment due to chemo-
therapy resistance, recurrence, and/or metastasis. The first of these trials examined 
temsirolimus with cetuximab and resulted in dose-limited toxicities in one-third 
of patients [51]. The second considered another mTOR inhibitor, everolimus, 
with erlotinib. This combination had a reasonable toxicity profile and stopped or 
decreased tumor growth in several patients, but it did not result in clinical benefit 
as compared to previous trials considering erlotinib as a monotherapy [52]. The 
third trial, which considered cetuximab with or without PI3K inhibitor PX-866, also 
did not provide evidence of improvement with the addition of PI3K inhibitor [53]. 
Several other trials using PI3K- and EGFR-targeting agents, sometimes alongside 
cytotoxic chemotherapy or radiotherapy, have been initiated and are in various 
stages of completion. Toxicity seems to be a major concern in many of these studies 
and may limit the use of such combinations in patients. As a result, the development 
of more specific combinations is warranted.
Nevertheless, previous work also suggests that the use of currently available 
PI3K and EGFR therapies may be optimized in other ways. For example, the 
sequence of combination treatments may be an important consideration. Lattanzio 
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et al. showed that Cal-33 cells responded to treatment with EGFR antibody followed 
by PI3K inhibitor [54], while other data show minimal responses in this model when 
EGFR- and PI3K-targeting small molecules were co-administered [31]. The type of 
EGFR-targeting agent that was used may also explain this conflicting data: small 
molecules (e.g., gefitinib, erlotinib, afatinib) and biologics (e.g., cetuximab) could 
have very different response profiles in combination with PI3K inhibitors.
Overall, although responses to PI3K and EGFR inhibitor combinations in 
HNSCC have been studied more extensively than many other dual-therapies for this 
cancer type, current results highlight the diversity of responses to agents target-
ing these two signaling pathways. Additional factors, including but not limited to 
timing, patient selection, and other co-treatments, require further consideration 
before compensation through the PI3K and EGFR pathways will be most effectively 
exploited in a population of HNSCC patients.
3.2 Other ERBB family members
Additional studies have successfully implicated other means of upstream inhibi-
tion in combination with PI3K-targeting drugs to improve responses in HNSCC, 
including other members of the ERBB family. While the structure of these members 
is similar to that of EGFR, each ERBB receptor has a different ligand binding speci-
ficity and physiological role [55]. Abnormalities of ERBB2, ERBB3, and ERBB4 have 
been reported in various malignancies such as breast cancer and occur in smaller 
subsets of head and neck cancer; therefore, they also became the targets for cancer 
therapies and have been considered in drug combinations [55, 56].
For example, Brand and co-authors blocked ERBB3 signaling as a means of 
reversing PI3K inhibitor resistance mediated by HPV oncoproteins E6 and E7 in 
HPV-positive HNSCCs [57]. These studies support the role of RTKs in HNSCC 
resistance mechanisms and validate that combination PI3K and RTK blockade may 
result in improved PI3K inhibitor responses. Likewise, Meister et al. also reported 
that PI3K inhibition induces ERBB3 upregulation and activation while the combi-
nation of PI3K and ERBB3 inhibition has synergistic effect, suppressing HNSCC 
growth both in vitro and in vivo [58]. Furthermore, in breast cancer, researchers 
also found that amplification of ERBB2 can activate PI3K-AKT signaling directly 
and indirectly [59], and ERBB2 inhibition potentiates the antitumor effect of PI3K 
inhibitor BEZ235 in this cancer type [60].
3.3 AXL receptor tyrosine kinase
PI3K inhibitor resistance mechanisms, of course, span far beyond the ERBB 
family of RTKs alone. For instance, the AXL receptor tyrosine kinase is highly 
expressed in various cancers including esophageal squamous cell carcinoma and 
HNSCC [61]. Based on work by Elkabets et al., AXL is upregulated particularly 
in PI3K inhibitor-resistant HNSCCs [62]. These researchers also showed that the 
dimerization of AXL and EGFR promotes signaling through PI3K and mTOR by 
activating the PLCγ-PKC signaling pathway, thereby limiting the efficacy of PI3K 
inhibitors. This PI3K-independent activation of mTOR counteracts the growth 
inhibitory effect of PI3K inhibition and mediates drug resistance in some head and 
neck models [62]. Further, Badarni et al. chose to identify and target the transcrip-
tion factors that were responsible for the increased expression of AXL in HNSCCs. 
In doing so, they discovered that a c-JUN, a member of the AP-1 transcription 
factor (TF) complex, was likely responsible for AXL upregulation and that blocking 
this TF improved the response to PI3K inhibitor BYL719 [63].
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3.4 Insulin-like growth factor-1 receptor (IGF-1R)
IGFR signaling is vital in the development of tissues [64] and is aberrantly 
implicated in several types of cancer including adenomas, breast cancer, lung can-
cer, ovarian cancer, and HNSCC [65]. IGF1R is amplified in 4% of HNSCC tumors 
from TCGA, placing it among the most commonly amplified genes in this tumor 
type [13–15]. Both IGF-1R and IGF binding protein-3 (IGFBP-3) have overt impact 
on HNSCC prognoses, as clinical data reveal that high expression of IGFBP-3 as well 
as the co-expression of IGFBP-3 with IGF-1R may predict poor prognosis in this 
cancer type [66]. Preclinical models also demonstrate the role of the IGF-1R signal-
ing pathway in HNSCC: small molecule IGF-1R inhibitor BMS-536924 is effective in 
both cell lines derived from transgenic mice that spontaneously developed salivary 
gland tumors and in xenograft mouse models [67].
The tyrosine kinase activity of IGF-1R suggests that the activation of IGF-1R 
could induce activation of PI3K signaling [68, 69]. Interestingly, studies suggest that 
the activation of mTOR signaling could be part of a negative feedback loop to reduce 
PI3K signaling by the phosphorylation of insulin receptor substrate-1 (IRS-1) [70]. 
This complex relationship between the PI3K and IGFR signaling pathways indicates 
that IGFR signaling could be a compensatory mechanism contributing to PI3K 
inhibitor resistance, a phenomenon that has been previously observed in multiple 
other cancer types [71, 72]. Recent data (submitted) also indicate the potential 
efficacy of PI3K and IGF-1R inhibitor combinations in HNSCC models, but such 
dual-therapies have yet to be evaluated in patients.
3.5 Anaplastic lymphoma kinase (ALK)
Aberration in the ALK gene is associated with several cancer types; gene fusions 
have been noted in anaplastic large cell lymphoma and one subset of non-small cell 
lung cancer [73], while mutations are present in nearly 15% of neuroblastomas [74]. 
ALK has also been shown to have a pleiotropic role in the aggressive growth and 
invasiveness of oral squamous cell carcinoma [75]. As a downstream member of 
the ALK signaling pathway, PI3K/AKT signaling may be activated followed by ALK 
activation [76]. Collectively, these data motivate consideration of ALK signaling 
as a compensatory signaling pathway responsible for resistance to PI3K inhibitor 
monotherapies.
ALK signaling has not historically been evaluated as a resistance mechanism in 
HNSCC, since fusion events are rare and ALK expression is often quite low in this 
cancer type. Nevertheless, recent work has shown that EGFR inhibitor treatments 
may increase the expression of ALK and display greater efficacy with ALK inhibi-
tors [77, 78]. Gonzales et al. showed that the combination of ALK inhibitor and 
EGFR inhibitor could decrease HNSCC cell proliferation in vitro as well as reduce 
the volumes of xenotransplantation tumors in vivo [77]. These studies demonstrate 
that ALK signaling is indeed an important mediator of drug resistance in some head 
and neck cancers. Additionally, ALK was also identified in a CRISPR/Cas9 knock-
out screen as one of the kinases responsible for resistance to PI3K inhibitor treat-
ment (submitted). PI3K and ALK dual-therapy, however, has not been considered 
in HNSCC. The only previous studies of PI3K and ALK inhibitors examine such 
combinations in the context of other tumor types driven by ALK signaling due to 
fusion with EML4 or other genes [79–82]. Our recent work shows that co-treatment 
with ALK inhibitor brigatinib and PI3K inhibitor pictilisib is synergistic in HNSCC 
models (submitted); this may represent the first evidence of interaction between 
PI3K and ALK signaling in the absence of ALK gene fusion.
9Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms
DOI: http://dx.doi.org/10.5772/intechopen.92875
However, brigatinib is not a perfectly selective inhibitor of ALK—it also 
displays activity at IGF-1R, EGFR, and other RTKs, especially at higher concen-
trations [83, 84]. While ALK inhibition may be an important component of the 
response to combinations of brigatinib and PI3K inhibitor, we cannot exclude the 
possibility that the blockade of IGF-1R and/or EGFR contribute at least partially 
to this response. Both small molecule profiling studies and subsequent validation 
analyses show that IGF-1R or EGFR inhibition can improve responses to PI3K-
targeting therapy, as noted above. Genetic knockouts of ALK and IGF1R that were 
generated in combination-responsive HSC-4 cells offer insight into the effect 
of blocking an individual RTK, mimicking a perfectly selective pharmacologic 
treatment. ALK knockout HSC-4 cells are more sensitive to monotherapy with 
AKT inhibitor GDC-0068 than wildtype HSC-4 cells. Responses to PI3K inhibi-
tion are not markedly different in the knockout model, suggesting that ALK 
alone may not be responsible for the synergy of ALK- and PI3K-targeting agents 
in HNSCC. In spite of this, ALK and IGF1R knockout cell lines display increased 
levels of p110alpha, the protein encoded by the PIK3CA gene (submitted). This 
indicates an important molecular relationship between the ALK, IGF-1R, and 
PI3K pathways and may explain the lack of response to PI3K inhibition in knock-
out cell lines.
While the mechanistic basis for responses to pictilisib and brigatinib has not 
been fully elucidated, co-treatment with these agents three times per week inhibited 
tumor growth in a cell line-derived xenograft mouse model (submitted). However, 
despite the significant result observed after a 3-week course with these inhibitors, 
tumors did progress as treatment continued for extended lengths of time. This 
observation is in support of the development of additional compensatory mecha-
nisms mediating treatment resistance. Although the combination of PI3K and ALK 
inhibitor extended survival for weeks past what would have been observed in mice 
with vehicle- and brigatinib-treated tumors, further exploration of compensa-
tory signaling in HNSCC and the development of improved treatment paradigms 
is needed.
3.6 Fibroblast growth factor receptor (FGFR)
FGFRs also have been nominated as a critical candidate for compensatory 
signaling pathway in HNSCC. After the binding of the fibroblast growth factor 
(FGF) ligands, the FGFR signaling pathway will modify downstream phosphory-
lation and gene expression. Importantly, this pathway also has a well-described 
role in HNSCC pathogenesis due to recurrent of genetic alterations that occur in 
the disease [85]. According to previous studies, recurrent FGFR1 amplification 
is present in 17% of OSCC cases [86]. A high level of FGFR2 expression, FGFR3 
expression and FGFR2/FGFR3 co-expression are also observed in HNSCC cell 
lines [87], and such alterations have been suggested to contribute to the early 
stages of tumor initiation and disease progression [88]. In fact, previous in vitro 
and in vivo studies show that inhibition of the FGFR signaling pathway could 
decrease the proliferation of HNSCC supporting cells (fibroblast and endothelial 
cells) and ultimately results in a decline of tumor cell proliferation through 
increased cell apoptosis [89]. Combinations of EGFR and FGFR inhibitors have 
been evaluated in both HNSCC and other cancers, most notably lung cancer  
[90, 91], but have not translated to the clinic due to toxic effects in patients [92]. 
Based on these and other data demonstrating the important role of FGFR signal-
ing in HNSCC [93], combinations of PI3K and FGFR inhibitors might be syner-
gistic in a subset of patients.
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3.7 Focal adhesion kinase (FAK)
Although most pathways nominated as drivers of PI3K inhibitor resistance are 
RTKs, a potential relationship between PI3K and the cytoplasmic FAK receptor 
has also been described. FAK, which is encoded by the Protein Tyrosine Kinase 2 
(PTK2) gene [94], has a wide range of intracellular functions, involving regula-
tion of cell adhesion, cell proliferation, migration, and cell apoptosis, all of which 
are commonly altered in head and neck cancer [95]. One previous study assessed 
147 HNSCC clinical tumor samples and reported FAK protein overexpression and 
PTK2 gene amplification in 62 and 39% of these samples, respectively, support-
ing a molecular role for this kinase in HNSCC [96]. FAK inhibitors serve to arrest 
the cell cycle and decrease tumor cell viability via the induction of apoptosis [97]. 
One such inhibitor, TAE226, is able to induce the tumor cell apoptosis and in turn 
suppress HNSCC growth in vitro; this inhibitor also blocked tumor growth, metas-
tasis, and angiogenesis in vivo [98]. The mechanisms by which the FAK signaling 
pathway is involved in tumor cell metastases and growth may be kinase-dependent; 
in this case, FAK is upstream of PI3K signaling pathway. One hypothesis is that 
activation of FAK could induce the PI3K and subsequent downstream signaling 
including remodeling of the cytoskeletal, matrix metalloproteinases (MMPs) as 
well as formation or turnover of focal adhesion. Such effects might contribute to the 
metastases of tumor cells. Activation of the FAK-PI3K signaling pathway has also 
been shown to inhibit tumor cell apoptosis [99–102]. Interestingly, loss of PTEN, 
has been shown to stimulate FAK and downstream targets [103]. However, a role 
for FAK inhibition has not been well described in cases of PIK3CA amplification or 
mutation. One clinical trial (NCT02372227) sought to evaluate the safety of com-
bining PI3K and FAK inhibitors VS-5584 and VS-6063 in malignant mesothelioma 
but was terminated prior to completion. A recent report (submitted) shows that 
FAK/IGF-1R inhibitor TAE226 may be synergistic with PI3K inhibitors in HNSCC 
cell lines and xenografts, but the contribution of FAK signaling and the mechanism 
for this effect have yet to be fully determined. Taken together, however, this col-
lection of data nominates FAK signaling as a means of resistance to PI3K inhibitor 
monotherapy in HNSCC.
3.8 Aurora kinase A (AURKA)
Aurora kinase A (AURKA) is another player identified as having a potentially 
indispensable role in PI3K inhibitor response in some HNSCCs. AURKA is one of 
the aurora serine-threonine kinase family members, which play an important role 
in the regulation of cell cycle and cell division by controlling mitosis and meiosis 
[104]. In normal cells, AURKA regulates mitosis by contributing to maturation 
of the centrosome, synthesizing of bipolar spindle, and controlling cytokinesis. 
Researchers also showed that the upregulation of AURKA is associated with worse 
prognosis and decreased survival of patients with HNSCCs [105–107]. These poor 
outcomes are postulated to result from associated centrosome abnormalities and 
chromosomal aneusomy as well as activation of the spindle assembly checkpoint 
[106, 108]. AURKA is also involved in both AKT and FAK signaling pathways, and 
this AURKA/AKT/FAK signaling axis can be responsible for the migration and 
invasion of HNSCCs [109]. Previous research shows that suppression of AURKA 
via shRNA could inhibit the ability of laryngeal carcinoma cells to grow and invade 
both in vitro and in vivo, suggesting that AURKA inhibitor monotherapy may have 
a substantial effect on oncogenic phenotypes in some models [110]. Furthermore, 
recent data (submitted) indicate that the regulation of cell cycle gene expression 
and protein levels, including AURKA, is reduced by synergistic PI3K inhibitor 
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dual-therapies. The altered function of AURKA shows that aurora kinases could 
play a pivotal compensatory signaling role in PI3K inhibitor resistance.
3.9 Cell apoptosis
Overactivation of PI3K/AKT pathway can inhibit tumor cell apoptosis and 
promote cell proliferation. The family of forkhead transcription factors (FOXOs) 
is among the specific downstream PI3K/AKT effectors involved in the regulation 
of cell apoptosis. The PI3K/AKT pathway mediates serine/threonine phosphoryla-
tion of FOXO transcription factors, which reverses the pro-apoptotic effect of 
FOXOs by downregulating the pro-apoptotic protein BIM, a Bcl-2 family member. 
Conversely, the use of PI3K and AKT inhibitors may induce cell apoptosis in vari-
ous tumor types, a phenomenon already detailed in breast cancer models [111]. 
PI3K/AKT inhibition reduces FOXO phosphorylation leading to the upregulation 
of BIM [112], an effect that may contribute to apoptosis. The role of specific 
FOXO family members and their transcriptional targets as well as how these func-
tions are altered by modulation of PI3K signaling has yet to be fully determined in 
HNSCC.
3.10 PDK1, AKT, and mTOR
Much of the previous work on compensatory resistance to PI3K inhibition has 
noted contributions from pathways downstream of PI3K or other codependent 
RTKs, including PDK1 [30], AKT [113], mTOR [114–116], and MEK [117, 118]. 
Previous publications [117, 118] show that inhibiting PI3K and MEK is function-
ally similar to inhibiting PI3K and EGFR (see above). Prior studies have also 
highlighted the importance of PI3K effector AKT in combination responses; these 
publications describe similar evidence of synergy when replacing PI3K inhibitors 
with AKT inhibition or siRNA [46] and report reduced AKT phosphorylation 
following combination PI3K and EGFR inhibitor treatments [44, 46, 47, 82, 119]. 
Similarly, the work of Sambandam et al. demonstrates the importance of PDK1 
inhibition in PI3K inhibitor responses by showing that: (1) reductions in the 
level of phosphorylated and total PDK1 were present in cell lines that were more 
sensitive to PI3K inhibition and (2) AKT inhibitor MK-2206 and PDK1 inhibitor 
GSK2334470 were synergistic when used together, recapitulating or exceeding the 
effects of PI3K inhibitor monotherapy [30]. In contrast, other analyses (submit-
ted) demonstrate that AKT phosphorylation was similarly reduced following 
treatment with PI3K monotherapy and ineffective combinations as compared to 
treatment with synergistic drug pairs. This may suggest that AKT inhibition is 
necessary, but not sufficient, for response to PI3K inhibitor therapy. PDK1 phos-
phorylation was also unchanged with PI3K mono- and dual-therapy in this recent 
dataset (submitted), and little benefit was noted with PDK1, AKT, or mTOR 
inhibitors to PI3K inhibitors. Based on these findings, it seems that although 
PDK1, AKT, and mTOR are downstream effectors common to PI3K and the other 
RTKs involved in synergistic drug pairs, additional mechanisms are responsible 
for combination effects.
Clinical data evaluating the contribution of targeting both PI3K and its down-
stream PI3K remain immature. Trials have been performed to determine the safe 
dose of PI3K inhibitor BEZ235 in combination with mTOR inhibitors RAD001 
(NCT01482156) or everolimus (NCT01508104), but results have yet to be pub-
lished. While there is a trial of PI3K/mTOR inhibitor bimiralisib (NCT03740100) 
currently ongoing, the contribution of PI3K and mTOR individually will be impos-
sible to ascertain from this study alone.
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3.11 Immunotherapy
Emerging data suggest that the PI3K pathway may interact with immune 
responses and improve the efficacy of immune checkpoint receptor (ICR) blockade. 
One indication of the involvement of the PI3K pathway in responses to immuno-
therapies is based on data using models with loss of tumor suppressor PTEN. In 
multiple cancer types, increased expression of programmed death ligand-1 (PD-
L1) has been observed in models with loss of PTEN [120–123], and there is some 
evidence that this may also be the case in HNSCC [123].
PI3K signaling also may interface with immune responses through its important 
role in cellular metabolism. In cancerous cells, the metabolic balance shifts from 
oxidative phosphorylation to aerobic glycolysis as part of a paradigm known as 
the Warburg effect [17]. A notable consequence of this effect is the inefficient use 
of glucose, which limits the maximum possible amount of ATP or energy. Since 
PI3K pathway activity contributes to glucose uptake and glycolysis [125], cancer 
cells displaying PI3K pathway activation (through PIK3CA mutation, PTEN loss or 
other genetic or functional changes) may utilize additional glucose from the tumor 
microenvironment. Nearby cytotoxic T-lymphocytes (CTLs) and other immuno-
modulatory cells, which require vast amounts of glucose to launch and maintain 
effective immune attack on tumor spread, are therefore in heated competition with 
PI3K pathway-activated cells for the limited glucose supply. As such, CTL activa-
tion, including migration to the tumor site, production of cytokines, and other 
immune functions, is limited and CTL exhaustion occurs more rapidly [126–130]. 
PI3K inhibition, however, alters cellular metabolism to prevent or delay CTL 
exhaustion and thereby allows for a faster and/or more durable CTL response.
Additionally, PI3K inhibition may enhance the effects of ICR blockade by 
preventing adaptive resistance. One mechanism that may blunt responses to ICR 
blockade involves the compensatory upregulation of other ICRs. Shayan and 
coworkers showed that in HNSCC tumor samples, two ICRs, programmed cell 
death receptor-1 (PD-1) and T-cell Ig and mucin domain-3 protein (TIM-3), were 
co-expressed on CTLs displaying high levels of exhaustion [131]. PD-1 blockade 
resulted in further upregulation of TIM-3; this upregulation was reversible using 
PI3K inhibition [131]. Thus, through multiple means, PI3K inhibition may augment 
responses to immunotherapy in HNSCC. Clinical trials to evaluate therapies that 
combine PI3K inhibitor and ICR blockade are ongoing (including NCT04317105 to 
evaluate PD-1 inhibitor nivolumab and PI3K inhibitor copanlisib in solid tumors), 
and the results of these studies will offer critical insights for the future of targeted 
and immunotherapies in HNSCC and other cancers.
4. Conclusions
Due to advances in diverse profiling strategies ranging from next generation 
sequencing to combinatorial high throughput small molecule profiling to pooled 
CRISPR and shRNA screens, recent technological advances have led to signifi-
cant scientific advances in understanding the mechanisms that drive response to 
PI3K inhibitors in HNSCC and other cancers. Indeed, the future is bright for the 
advancement of PI3K inhibitors, especially as combination therapies, in HNSCC 
and other cancer types. Nevertheless, multiple questions remain regarding the 
role of specific signaling pathways in PI3K inhibitor resistance, and additional 
studies will be required to further our understanding of this important intersec-
tion of pharmacology and cancer biology. More work is needed to develop safer, 
more effective drugs, to establish biomarkers for response, and to target critical 
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